---
document_datetime: 2026-02-23 17:25:00
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/inluriyo.html
document_name: inluriyo.html
version: success
processing_time: 0.0951969
conversion_datetime: 2026-02-25 11:33:55.097626
docling_version:
  docling-serve: 1.13.1
  docling-jobkit: 1.11.0
  docling: 2.74.0
  docling-core: 2.65.2
  docling-ibm-models: 3.11.0
  docling-parse: 5.3.4
  python: cpython-313 (3.13.11)
  plaform: macOS-26.3-arm64-arm-64bit-Mach-O
---
# Inluriyo

[RSS](/en/individual-human-medicine.xml/270395)

Authorised

This medicine is authorised for use in the European Union

imlunestrant Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Inluriyo](#news-on)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Inluriyo is an anti-hormonal cancer medicine used on its own in adults to treat breast cancer that is locally advanced (has spread nearby) or metastatic (has spread to other parts of the body).

It can only be used when the cancer cells have receptors (targets) for the hormone oestrogen on their surface (oestrogen receptor-positive; ER-positive) and do not have large quantities of a receptor for human epidermal growth factor called HER2 (HER2-negative). The cancer cells must also have been shown to have a specific mutation (change) in the gene called *ESR1* .

Inluriyo is used in adults whose cancer has progressed further following previous treatment with hormone-based medicines. When the medicine is used in women who have not yet reached the menopause (pre-menopausal or perimenopausal) and men, it should be given with a luteinising hormone-releasing hormone (LHRH) agonist (a medicine that lowers blood levels of the hormones oestrogen and progesterone).

Inluriyo contains the active substance imlunestrant.

Expand section

Collapse section

## How is Inluriyo used?

Inluriyo can only be obtained with a prescription, and treatment should be started and supervised by a doctor experienced in the use of cancer medicines.

Inluriyo is available as tablets to be taken by mouth once a day. Treatment should continue as long as the patient benefits from it or until they develop unacceptable side effects.

For more information about using Inluriyo, see the package leaflet or contact your doctor or pharmacist.

## How does Inluriyo work?

ER-positive breast cancer is stimulated to grow when the hormone oestrogen attaches to ER receptors on cancer cells. The active substance in Inluriyo, imlunestrant, blocks and destroys these receptors; as a result, oestrogen no longer stimulates these cancer cells to grow which slows down the growth of the cancer.

## What benefits of Inluriyo have been shown in studies?

A main study showed that Inluriyo increased the time adults with ER-positive, HER2-negative breast cancer with an *ESR1* mutation lived without their cancer getting worse compared with standard of care (hormone-based treatment that medical experts consider most appropriate).

The study involved 874 adults with ER-positive, HER2-negative breast cancer that was locally advanced or had started to spread, and whose cancer had come back or did not respond following previous treatment with a hormone-based medicine. The study involved participants with and without an *ESR1* mutation.

Participants were given either Inluriyo on its own, standard of care or Inluriyo given with abemaciclib, another cancer medicine. Those given Inluriyo (331 people) and standard of care (330 people) both lived on average for around 5.5 months without their cancer getting worse. However, those with an *ESR1* mutation given Inluriyo on its own (138 people) lived on average for around 5.5 months without their cancer getting worse compared with around 3.8 months for those with an *ESR1* mutation given standard of care (118 people).

## What are the risks associated with Inluriyo?

For the full list of side effects and restrictions with Inluriyo, see the package leaflet.

The most common side effects with Inluriyo (which may affect more than 1 in 10 people) include increased liver enzymes (proteins) which can be a sign of liver problems, tiredness, diarrhoea, nausea (feeling sick) and vomiting.

Inluriyo must not be used in women who are breast-feeding.

## Why is Inluriyo authorised in the EU?

Inluriyo was shown to be effective at increasing the time before the disease got worse in adults with ER-positive, HER2-negative breast cancer with an *ESR1* mutation that was locally advanced or had started to spread, and whose cancer did not respond following treatment with a hormone-based medicine. However, there were some limitations with the main study including a limited number of patients with an *ESR1* mutation included in the study. Furthermore, there was only a small difference between the benefits observed with Inluriyo and those achieved with standard of care.

Overall, the safety profile of Inluriyo was considered similar to that of hormone-based cancer treatments; the main difference is that more side effects affecting the stomach and gut were observed with Inluriyo compared with hormone-based treatments.

The European Medicines Agency therefore decided that Inluriyo's benefits are greater than its risks and that it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Inluriyo?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Inluriyo have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Inluriyo are continuously monitored. Suspected side effects reported with Inluriyo are carefully evaluated and any necessary action taken to protect patients.

## Other information about Inluriyo

Inluriyo received a marketing authorisation valid throughout the EU on 9 January 2026.

Inluriyo : EPAR - Medicine overview

Reference Number: EMA/372914/2025

English (EN) (123.65 KB - PDF)

**First published:** 23/01/2026

[View](/en/documents/overview/inluriyo-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-570)

български (BG) (145.87 KB - PDF)

**First published:**

23/01/2026

[View](/bg/documents/overview/inluriyo-epar-medicine-overview_bg.pdf)

español (ES) (123.33 KB - PDF)

**First published:**

23/01/2026

[View](/es/documents/overview/inluriyo-epar-medicine-overview_es.pdf)

čeština (CS) (144.51 KB - PDF)

**First published:**

23/01/2026

[View](/cs/documents/overview/inluriyo-epar-medicine-overview_cs.pdf)

dansk (DA) (121.94 KB - PDF)

**First published:**

23/01/2026

[View](/da/documents/overview/inluriyo-epar-medicine-overview_da.pdf)

Deutsch (DE) (125.92 KB - PDF)

**First published:**

23/01/2026

[View](/de/documents/overview/inluriyo-epar-medicine-overview_de.pdf)

eesti keel (ET) (119.58 KB - PDF)

**First published:**

23/01/2026

[View](/et/documents/overview/inluriyo-epar-medicine-overview_et.pdf)

ελληνικά (EL) (150.93 KB - PDF)

**First published:**

23/01/2026

[View](/el/documents/overview/inluriyo-epar-medicine-overview_el.pdf)

français (FR) (130.03 KB - PDF)

**First published:**

23/01/2026

[View](/fr/documents/overview/inluriyo-epar-medicine-overview_fr.pdf)

hrvatski (HR) (119.19 KB - PDF)

**First published:**

23/01/2026

[View](/hr/documents/overview/inluriyo-epar-medicine-overview_hr.pdf)

italiano (IT) (117.21 KB - PDF)

**First published:**

23/01/2026

[View](/it/documents/overview/inluriyo-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (128.33 KB - PDF)

**First published:**

23/01/2026

[View](/lv/documents/overview/inluriyo-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (119.26 KB - PDF)

**First published:**

23/01/2026

[View](/lt/documents/overview/inluriyo-epar-medicine-overview_lt.pdf)

magyar (HU) (119.81 KB - PDF)

**First published:**

23/01/2026

[View](/hu/documents/overview/inluriyo-epar-medicine-overview_hu.pdf)

Malti (MT) (147.19 KB - PDF)

**First published:**

23/01/2026

[View](/mt/documents/overview/inluriyo-epar-medicine-overview_mt.pdf)

Nederlands (NL) (122.62 KB - PDF)

**First published:**

23/01/2026

[View](/nl/documents/overview/inluriyo-epar-medicine-overview_nl.pdf)

polski (PL) (148.54 KB - PDF)

**First published:**

23/01/2026

[View](/pl/documents/overview/inluriyo-epar-medicine-overview_pl.pdf)

português (PT) (123.99 KB - PDF)

**First published:**

23/01/2026

[View](/pt/documents/overview/inluriyo-epar-medicine-overview_pt.pdf)

română (RO) (142.98 KB - PDF)

**First published:**

23/01/2026

[View](/ro/documents/overview/inluriyo-epar-medicine-overview_ro.pdf)

slovenčina (SK) (145.92 KB - PDF)

**First published:**

23/01/2026

[View](/sk/documents/overview/inluriyo-epar-medicine-overview_sk.pdf)

slovenščina (SL) (142.69 KB - PDF)

**First published:**

23/01/2026

[View](/sl/documents/overview/inluriyo-epar-medicine-overview_sl.pdf)

Suomi (FI) (120.42 KB - PDF)

**First published:**

23/01/2026

[View](/fi/documents/overview/inluriyo-epar-medicine-overview_fi.pdf)

svenska (SV) (121.33 KB - PDF)

**First published:**

23/01/2026

[View](/sv/documents/overview/inluriyo-epar-medicine-overview_sv.pdf)

Inluriyo : EPAR - Risk management plan

English (EN) (791.55 KB - PDF)

**First published:** 23/01/2026

[View](/en/documents/rmp/inluriyo-epar-risk-management-plan_en.pdf)

## Product information

Inluriyo : EPAR - Product information

English (EN) (544.74 KB - PDF)

**First published:** 23/01/2026

**Last updated:** 23/02/2026

[View](/en/documents/product-information/inluriyo-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-193)

български (BG) (675.93 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/bg/documents/product-information/inluriyo-epar-product-information_bg.pdf)

español (ES) (559.52 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/es/documents/product-information/inluriyo-epar-product-information_es.pdf)

čeština (CS) (643.54 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/cs/documents/product-information/inluriyo-epar-product-information_cs.pdf)

dansk (DA) (423.73 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/da/documents/product-information/inluriyo-epar-product-information_da.pdf)

Deutsch (DE) (657.75 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/de/documents/product-information/inluriyo-epar-product-information_de.pdf)

eesti keel (ET) (492.26 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/et/documents/product-information/inluriyo-epar-product-information_et.pdf)

ελληνικά (EL) (638.45 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/el/documents/product-information/inluriyo-epar-product-information_el.pdf)

français (FR) (498.29 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/fr/documents/product-information/inluriyo-epar-product-information_fr.pdf)

hrvatski (HR) (663.96 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/hr/documents/product-information/inluriyo-epar-product-information_hr.pdf)

íslenska (IS) (455.06 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/is/documents/product-information/inluriyo-epar-product-information_is.pdf)

italiano (IT) (529.86 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/it/documents/product-information/inluriyo-epar-product-information_it.pdf)

latviešu valoda (LV) (491.64 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/lv/documents/product-information/inluriyo-epar-product-information_lv.pdf)

lietuvių kalba (LT) (739.91 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/lt/documents/product-information/inluriyo-epar-product-information_lt.pdf)

magyar (HU) (482.13 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/hu/documents/product-information/inluriyo-epar-product-information_hu.pdf)

Malti (MT) (547.15 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/mt/documents/product-information/inluriyo-epar-product-information_mt.pdf)

Nederlands (NL) (544.37 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/nl/documents/product-information/inluriyo-epar-product-information_nl.pdf)

norsk (NO) (553.64 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/no/documents/product-information/inluriyo-epar-product-information_no.pdf)

polski (PL) (504.26 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/pl/documents/product-information/inluriyo-epar-product-information_pl.pdf)

português (PT) (543.17 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/pt/documents/product-information/inluriyo-epar-product-information_pt.pdf)

română (RO) (457.75 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/ro/documents/product-information/inluriyo-epar-product-information_ro.pdf)

slovenčina (SK) (540.95 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/sk/documents/product-information/inluriyo-epar-product-information_sk.pdf)

slovenščina (SL) (507.88 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/sl/documents/product-information/inluriyo-epar-product-information_sl.pdf)

Suomi (FI) (611.52 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/fi/documents/product-information/inluriyo-epar-product-information_fi.pdf)

svenska (SV) (484.07 KB - PDF)

**First published:**

23/01/2026

**Last updated:**

23/02/2026

[View](/sv/documents/product-information/inluriyo-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000333242 20/02/2026

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

Inluriyo : EPAR - All authorised presentations

English (EN) (74.94 KB - PDF)

**First published:** 23/01/2026

[View](/en/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_en.pdf)

[Other languages (24)](#file-language-dropdown-609)

български (BG) (83.07 KB - PDF)

**First published:**

23/01/2026

[View](/bg/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_bg.pdf)

español (ES) (108.08 KB - PDF)

**First published:**

23/01/2026

[View](/es/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_es.pdf)

čeština (CS) (75.86 KB - PDF)

**First published:**

23/01/2026

[View](/cs/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_cs.pdf)

dansk (DA) (75.37 KB - PDF)

**First published:**

23/01/2026

[View](/da/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_da.pdf)

Deutsch (DE) (65.62 KB - PDF)

**First published:**

23/01/2026

[View](/de/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_de.pdf)

eesti keel (ET) (75.94 KB - PDF)

**First published:**

23/01/2026

[View](/et/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_et.pdf)

ελληνικά (EL) (78.29 KB - PDF)

**First published:**

23/01/2026

[View](/el/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_el.pdf)

français (FR) (75.93 KB - PDF)

**First published:**

23/01/2026

[View](/fr/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_fr.pdf)

hrvatski (HR) (91.46 KB - PDF)

**First published:**

23/01/2026

[View](/hr/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_hr.pdf)

íslenska (IS) (74.72 KB - PDF)

**First published:**

23/01/2026

[View](/is/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_is.pdf)

italiano (IT) (68.52 KB - PDF)

**First published:**

23/01/2026

[View](/it/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_it.pdf)

latviešu valoda (LV) (83.07 KB - PDF)

**First published:**

23/01/2026

[View](/lv/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_lv.pdf)

lietuvių kalba (LT) (89.71 KB - PDF)

**First published:**

23/01/2026

[View](/lt/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_lt.pdf)

magyar (HU) (83.27 KB - PDF)

**First published:**

23/01/2026

[View](/hu/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_hu.pdf)

Malti (MT) (82.76 KB - PDF)

**First published:**

23/01/2026

[View](/mt/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_mt.pdf)

Nederlands (NL) (66.31 KB - PDF)

**First published:**

23/01/2026

[View](/nl/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_nl.pdf)

norsk (NO) (66.62 KB - PDF)

**First published:**

23/01/2026

[View](/no/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_no.pdf)

polski (PL) (88.49 KB - PDF)

**First published:**

23/01/2026

[View](/pl/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_pl.pdf)

português (PT) (75.42 KB - PDF)

**First published:**

23/01/2026

[View](/pt/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_pt.pdf)

română (RO) (70.82 KB - PDF)

**First published:**

23/01/2026

[View](/ro/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_ro.pdf)

slovenčina (SK) (90.13 KB - PDF)

**First published:**

23/01/2026

[View](/sk/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_sk.pdf)

slovenščina (SL) (83.09 KB - PDF)

**First published:**

23/01/2026

[View](/sl/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_sl.pdf)

Suomi (FI) (74.15 KB - PDF)

**First published:**

23/01/2026

[View](/fi/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_fi.pdf)

svenska (SV) (71.54 KB - PDF)

**First published:**

23/01/2026

[View](/sv/documents/all-authorised-presentations/inluriyo-epar-all-authorised-presentations_sv.pdf)

## Product details

Name of medicine Inluriyo Active substance imlunestrant tosilate International non-proprietary name (INN) or common name imlunestrant Therapeutic area (MeSH) Breast Neoplasms Anatomical therapeutic chemical (ATC) code L02BA

### Pharmacotherapeutic group

Endocrine therapy

### Therapeutic indication

Inluriyo is indicated as monotherapy for the treatment of adult patients with oestrogen receptor (ER)-positive, HER2-negative, locally advanced or metastatic breast cancer with an activating ESR1-mutation, who have disease progression following prior treatment with an endocrine based regimen (for biomarker-based patient selection, see section 4.2). In pre- or perimenopausal women, or men, Inluriyo should be combined with a luteinising hormone-releasing hormone (LHRH) agonist.

## Authorisation details

EMA product number EMEA/H/C/006184

Additional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under [additional monitoring](/node/68821) .

Marketing authorisation holder

Eli Lilly Nederland B.V.

Orteliuslaan 1000 3528 BD Utrecht Netherlands

Opinion adopted 13/11/2025 Marketing authorisation issued 09/01/2026 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Inluriyo : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (142.55 KB - PDF)

**First published:** 23/02/2026

[View](/en/documents/procedural-steps-after/inluriyo-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Inluriyo : EPAR - Public assessment report

Adopted

Reference Number: EMA/CHMP/310589/2025

English (EN) (9.96 MB - PDF)

**First published:** 23/01/2026

[View](/en/documents/assessment-report/inluriyo-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Inluriyo

Adopted

Reference Number: EMA/CHMP/354855/2025

English (EN) (146.67 KB - PDF)

**First published:** 14/11/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-inluriyo_en.pdf)

## News on Inluriyo

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 10-13 November 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-10-13-november-2025) 14/11/2025

**This page was last updated on** 23/02/2026

## Share this page

[Back to top](#main-content)